Article: Cantab Pharmaceuticals Reports Second Quarter Results

CAMBRIDGE, England, Aug. 12 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY) today announced financial results for the second quarter ended June 30, 1996.

Revenues for the second quarter of 1996 were 8,000 pounds sterling, compared to 35,000 pounds for the same period in 1995. Revenues for the first six months of 1996 were 25,000 pounds, compared to 170,000 pounds for 1994. In 1996, revenues comprised contract development fees earned under Cantab's current collaborative agreement with Pfizer Animal Health Group in 1996, and in 1995, revenues comprised contract development fees earned under Cantab's collaborative agreement with Baxter Healthcare ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!